ストックスクリーナーアプリを入手
1.9689
2.88%
0.0389
前日終値:
$1.93
開ける：
$1.98
24時間の取引高:
106.34K
Relative Volume:
0.10
時価総額：
$69.67M
収益：
$832.00K
当期純損益:
$-135.12M
株価収益率:
-0.3233
EPS:
-6.09
ネットキャッシュフロー:
$-124.69M
1週間 パフォーマンス:
+1.82%
1か月 パフォーマンス:
-7.65%
6か月 パフォーマンス:
-70.84%
1年 パフォーマンス:
-81.63%
1日の値動き範囲:
$1.95
$2.015
1週間の範囲:
$1.90
$2.075
52週間の値動き範囲:
$1.74
$14.75
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
名前
Inovio Pharmaceuticals Inc
セクター
電話
(858) 410-3134
住所
6769 MESA RIDGE RD., SAN DIEGO, PA
INO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.97 | 69.67M | 832.00K | -135.12M | -124.69M | -6.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
509.43 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.41 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
593.77 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.40 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.39 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-14 | 開始されました | Stephens | Overweight |
| 2024-01-25 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-11-09 | ダウングレード | Maxim Group | Buy → Hold |
| 2022-11-01 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-07-19 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-01-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-12-29 | 再開されました | Jefferies | Hold |
| 2021-09-10 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-06-24 | 開始されました | Jefferies | Hold |
| 2021-03-23 | 開始されました | BofA Securities | Neutral |
| 2021-02-12 | 開始されました | Oppenheimer | Outperform |
| 2020-11-17 | ダウングレード | ROTH Capital | Neutral → Sell |
| 2020-11-10 | アップグレード | ROTH Capital | Sell → Neutral |
| 2020-09-28 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-01 | ダウングレード | Maxim Group | Buy → Hold |
| 2020-07-01 | ダウングレード | ROTH Capital | Neutral → Sell |
| 2020-06-29 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | ダウングレード | Stifel | Buy → Hold |
| 2020-05-21 | 開始されました | The Benchmark Company | Buy |
| 2020-04-30 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2020-03-13 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | 開始されました | ROTH Capital | Buy |
| 2018-02-15 | 繰り返されました | Maxim Group | Buy |
| 2017-10-18 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-09-06 | 開始されました | Citigroup | Buy |
| 2017-06-08 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | 繰り返されました | Maxim Group | Buy |
| 2017-03-16 | アップグレード | Maxim Group | Hold → Buy |
| 2017-03-16 | ダウングレード | Piper Jaffray | Overweight → Neutral |
すべてを表示
Inovio Pharmaceuticals Inc (INO) 最新ニュース
Inovio Pharmaceuticals Reports Interim Trial Results of DNA-Encoded Monoclonal Antibodies for COVID-19 - Marketscreener.com
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19 - PR Newswire
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025 - BioSpace
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
INOVIO Earnings Alert: Key Q4 and 2024 Financial Results Coming March 18What to Watch - StockTitan
Recurrent Respiratory Papillomatosis Market Set to Grow - openPR
Inovio Pharmaceuticals : to start global late-stage COVID-19 vaccine trial this summer -May 10, 2021 at 06:41 pm EDT - Marketscreener.com
Inovio Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Anus Neoplasms Treatment Market Size Report 2032 | Inovio - openPR
Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) PT at $12.40 - Defense World
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Inovio Pharmaceuticals (INO) Expected to Announce Earnings on Wednesday - MarketBeat
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Cervical Dysplasia Market to Show Remarkable Growth Trends from - openPR
Inovio Pharmaceuticals to Host Third Quarter 2013 Earnings Webcast Live on Tuesday, November 12, 2013 - ACCESS Newswire
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Inovio Investor Alert: Class Action Lawsuit Filed - ACCESS Newswire
Inovio Pharma Stock Slips Ahead of Q3 Earnings: Retail’s Bullish - MSN
INOVIO’s INO-3107 Shows Powerful Potential for Treating Recurrent Respiratory Papillomatosis - MyChesCo
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Inovio Pharmaceuticals (INO) Investors with $100K Losses to Contact its Attorneys: Firm Investigating Possible Securities Fraud - ACCESS Newswire
INOVIO to Highlight Breakthrough Immunotherapy Data at AACR Conference - MSN
INO-3107 shows promise in reducing surgeries for RRP patients By Investing.com - Investing.com Canada
INOVIO Advances INO-3107 Into BLA Submission After Positive Phase 1/2 Trial Results For RRP - Nasdaq
INOVIO Announces Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as A Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications - Marketscreener.com
Here's Why Inovio (INO) Could be Great Choice for a Bottom Fisher - Zacks Investment Research
INO-3107 shows promise in reducing surgeries for RRP patients - Investing.com India
Inovio Pharmaceuticals' Phase 1/2 Study Results Published In Nature Communications - Marketscreener.com
Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications - PR Newswire
Zika Vaccines Market Poised for Breakthrough Growth by 2032 | Rising Demand & Key Innovations: Sanofi S.A, - EIN News
Immune Response Data For INO-3107 To Be Presented As A Poster At American Association For Cancer Research Immuno-Oncology Conference - Marketscreener.com
Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference - Quantisnow
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Price Target at $12.40 - Defense World
DNA Nanotechnology Market Overall Study Report 2025-2032 | - openPR
BlackRock, Inc. Expands Stake in Inovio Pharmaceuticals Inc. - GuruFocus.com
Anal Cancer Market Forecast 2034: Clinical Trials, Medication, - openPR
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
INOVIO Reports Inducement Grant Under Inducement Plan - GuruFocus.com
INOVIO to Present at Oppenheimer Healthcare Life Sciences Conference - MyChesCo
Vanguard Group Inc. Reduces Stake in Inovio Pharmaceuticals Inc. - GuruFocus.com
INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - StreetInsider.com
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
INOVIO's Next Big Move: CEO Reveals Future of DNA Medicine at Major Healthcare Conference - StockTitan
Inovio Pharmaceuticals Inc (INO) 財務データ
収益
当期純利益
現金流量
EPS
1.28%
0.80%
大文字化:
|
ボリューム (24 時間):